Our radiopharmaceutical CDMO services support your drug from early development to commercial production, ensuring speed, efficiency, and regulatory compliance.
Whether you have a new drug molecule and are seeking research and development support for drug approval, an FDA-approved drug seeking additional manufacturing space, or anywhere in between, we can scale our services to support you.
We provide the ideal environment for your preclinical research and development: A cutting-edge facility with 2,000 sq. feet of dedicated R&D space. Regardless of your isotope, we have the capacity, resources, and expertise to support the advancement of your radiotherapy or theranostic.
Supply chain hurdles shouldn’t stand in the way of getting your radiopharmaceuticals to patients. Our isotope-agnostic approach and specialized logistics mean we can mitigate delays to deliver your products safely, on time, and exactly where they’re needed.
With a state-of-the-art operational facility in Rochester, MN, and two expansion sites underway, we provide the capacity and specialized infrastructure needed to support radiopharmaceutical manufacturing at any stage—from clinical trials to commercial production.
Our proactive approach to radiopharmaceutical quality assurance, rigorous quality control measures, purpose-built facilities, and decades of specialized experience mean we help you avoid costly setbacks and maintain seamless radiopharmaceutical production.
Our team of seasoned industry leaders brings 150+ collective years of experience in manufacturing and 250+ collective years of experience in radiopharmaceutical supply chain to the table.
Building development and manufacturing facilities near prominent destination medical centers and key distribution hubs allows us to expedite drug production and ensure your life-extending treatments reach patients precisely when they need them.
We’ve woven a tight web across the entire supply chain with our customers in mind—from hospitals and universities to radioisotope suppliers and regulatory agencies. This interconnected network gives us unparalleled insights and resources to navigate the complex world of radiotherapies.
To avoid potential conflicts of interest, risks to your intellectual property, and issues with resource allocation, our sole focus is your drug—we don’t develop our own.
